ClinicalTrials.gg
CompletedNCT07001501Updated Jun 3, 2025

A Clinical Study of the Interactions Between Azvudine Tablets (FNC) and Itraconazole Capsules (ICZ)

A Phase 1 interventional study of Azvudine tablets(FNC) and Itraconazole Capsules (ICZ) and Azvudine tablets(FNC) and Itraconazole Capsules (ICZ) in Healthy, sponsored by Henan Genuine Biotech Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-03.

Sponsored by Henan Genuine Biotech Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years 3 months after the study started (first participant enrolled Feb 2022, registered May 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Azvudine(FNC),a nucleoside reverse transcriptase inhibitor, make itself a better candidate to be co-formulated in other anti-HIV therapies, thus to improve patient's compliance. FNC is a broad-spectrum RNA virus inhibitor that inhibits the novel coronavirus RNA-dependent RNA polymerase (RdRp).

This is a clinical study to evaluate the Interactions between Azvudine Tablets (FNC) and Itraconazole Capsules (ICZ) in healthy subjects. This is a single-center, randomized, open-label, three-cycles, three-treatment crossover clinical trial. Subjects was administered orally for 10 consecutive days each cycle, and the washout period between each cycle was 14 days. Biological sample collection and safety examination were performed.

02

Conditions studied

  • Healthy

Keywords

  • Azvudine
03

In context

Lead sponsor

Henan Genuine Biotech Co., Ltd. is the lead sponsor of 13 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male or female subjects aged 18 years or older (including 18 years) with an appropriate ratio of male to female participants;
  2. The weight of men should be ≥ 50.0kg, and the weight of women should be ≥ 45.0kg. (BMI) within the range of 19.0-26.0 (including the critical value).;
  3. All fertile male and female subjects agreed to take appropriate and effective physical measures from the screening period until the end of the trial, and to use effective physical and/or pharmacological contraceptive measures for 6 months after the trial ends, with no plans for sperm or egg donation;
  4. Subjects fully understand the purpose, nature, process of the trial, and the potential adverse reactions, voluntarily agree to participate as subjects, and sign an form prior to the commencement of all study procedures;
  5. Subjects must be able to communicate effectively with the researchers and understand and comply with all requirements of this study.

Exclusion criteria

Exclusion Criteria:

  1. Individuals with allergic constitutions, a history of drug or food allergies, especially those allergic to any components of this product and its ;
  2. Individuals with a previous history of hypoglycemia;
  3. Individuals who have abnormal results from physical examinations, vital signs check, clinical laboratory tests, 12-lead , and other pre-trial relevant examinations, deemed by the clinical researcher, and considered unqualified (normal reference range for vital signs: systolic blood pressure \<90 mmHg or >140 mmHg, diastolic blood pressure \<60 mmHg or >90 mmHg; pulse \<60 bpm or >100 bpm);
  4. Individuals with a history of alcohol abuse within the 12 months prior to screening (consuming ≥14 units of alcohol weekly: 1 unit = 285 ml of beer, or 25 ml of spirits, or 150 ml of wine) or those with positive alcohol breath test results before enrollment (test value >0 mg/100 ml);
  5. Individuals with a history of drug abuse or use of illicit substances within the 12 months prior to screening, including repeated or excessive use of various anesthetics and psychoactive substances, addictive drugs [MDMA (Ecstasy), Methamphetamine (Ice), Ketamine, Morphine, THC (Marijuana)] or those with a positive result on the five-panel drug test before enrollment;
  6. Individuals who had undergone surgery within 3 months prior to screening, especially those who had surgeries affecting drug absorption, distribution, metabolism, or excretion, or who plan to undergo surgery during the study;
  7. Individuals who had used any drug that interacts with the trial medication within 30 days prior to screening, such as methadone, disopyramide, dofetilide, dronedarone, quinidine, ergot alkaloids (such as dihydroergotamine, ergometrine, ergotamine, methylergometrine), irinotecan, lurasidone, oral midazolam, pimozide, triazolam, felodipine, nisoldipine, ranolazine, eplerenone, cisapride, lovastatin, simvastatin, ticagrelor, medium or strong inducers such as levoacemesadol, halofantrine, astemizole, imidolastine, terfenadine, serindole, benzylprodil, lecadipine, ivabradidine, domperidone and other CYP3A4 medium or strong inducers or CYP3A4/P-glycoprotein/BCRP substrates and erythromycin, azithromycin, levoxacin, etc.;
  8. Individuals with a past medical history of cardiovascular, liver, kidney, pulmonary, gastrointestinal, neurological diseases, particularly any surgical conditions or diseases that might affect drug absorption, distribution, metabolism, and excretion, or conditions that could pose risks to trial participants;
  9. Individuals with a history of mental illness (e.g., anxiety, depression);
  10. Individuals with febrile illnesses within 3 days prior to screening;
  11. Individuals who had received a novel coronavirus vaccine within 14 days prior to screening or received any other vaccine within 3 months prior to screening, or planed to receive a vaccine during the study;
  12. Individuals who had participated in other clinical trials and received medication within 3 months prior to screening;
  13. Individuals who consumed excessive amounts of tea, coffee, and/or beverages rich in caffeine, theobromine, and alcohol (more than 8 cups, with 1 cup = 250 ml) within 3 months prior to screening;
  14. Individuals who had used any prescription medications, over-the-counter drugs, herbal medicines, dietary supplements, and functional vitamins within 14 days before the first dose;
  15. Individuals who smoked an average of more than 5 cigarettes daily within 3 months prior to the first dose;
  16. Individuals who had donated blood or experienced significant blood loss (greater than 400 ml, excluding normal physiological bleeding in women) within 3 months prior to the first dose, or who planed to donate blood or blood components during the study or within one week after the study;
  17. Females who tested positive for pregnancy; pregnant or breastfeeding women; female participants who engaged in unprotected sexual intercourse with a partner within 14 days prior to the trial;
  18. Individuals with poor conditions for vascular puncture, or who could not tolerate venous blood sampling, and/or had a history of vasovagal syncope;
  19. Individuals deemed unsuitable for this study by the investigator.

(19) Individuals deemed unsuitable for this study by the investigator.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Group 1 : FNC+ICZ;FNC;ICZ

    Drug: Azvudine tablets(FNC) and Itraconazole Capsules (ICZ)

  • Experimental
    Group 2 : ICZ;FNC+ICZ; FNC

    Drug: Azvudine tablets(FNC) and Itraconazole Capsules (ICZ)

  • Experimental
    Group 3 : FNC; ICZ; FNC+ICZ

    Drug: Azvudine tablets(FNC) and Itraconazole Capsules (ICZ)

Interventions

  • DrugAzvudine tablets(FNC) and Itraconazole Capsules (ICZ)

    Drug pages: Azvudine · Itraconazole

    This study consisted of 3 cycles, each cycle was administered orally for 10 consecutive days, and the washout period between each cycle was 14 days. Subjects were administered the drug as follow: FNC 3 mg (1 tablet)+ICZ 200 mg (2 capsules) (taken at the same time), 1 time a day, orally, for 10 consecutive days; FNC: 3 mg (1 tablet) each time, 1 time a day, orally, for 10 consecutive days; ICZ: 200 mg (2 capsules) each time, 1 time a day, orally, for 10 consecutive days.

  • DrugAzvudine tablets(FNC) and Itraconazole Capsules (ICZ)

    Drug pages: Azvudine · Itraconazole

    This study consisted of 3 cycles, each cycle was administered orally for 10 consecutive days, and the washout period between each cycle was 14 days. Subjects were administered the drug as follow: ICZ: 200 mg (2 capsules) each time, 1 time a day, orally, for 10 consecutive days; FNC 3 mg (1 tablet)+ICZ 200 mg (2 capsules) (taken at the same time), 1 time a day, orally, for 10 consecutive days; FNC: 3 mg (1 tablet) each time, 1 time a day, orally, for 10 consecutive days.

  • DrugAzvudine tablets(FNC) and Itraconazole Capsules (ICZ)

    Drug pages: Azvudine · Itraconazole

    This study consisted of 3 cycles, each cycle was administered orally for 10 consecutive days, and the washout period between each cycle was 14 days. Subjects were administered the drug as follow: FNC: 3 mg (1 tablet) each time, 1 time a day, orally, for 10 consecutive days; ICZ: 200 mg (2 capsules) each time, 1 time a day, orally, for 10 consecutive days; FNC 3 mg (1 tablet)+ICZ 200 mg (2 capsules) (taken at the same time), 1 time a day, orally, for 10 consecutive days.

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Maximum Plasma Concentration at Steady State (Cmax, ss) of Azvudine and Itraconazole

    Time frame: Blood samples were collected on Day 8, 9, 10, 31, 32, 33, 54, 55 and 56 of the study.

  2. Pharmacokinetics (PK): Time to Maximum Plasma Concentration at Steady State (Tmax, ss) of Azvudine and Itraconazole

    Time frame: Blood samples were collected on Day 8, 9, 10, 31, 32, 33, 54, 55 and 56 of the study.

  3. Pharmacokinetics (PK): Elimination of Terminal Half-Life (t1/2) of Azvudine and Itraconazole

    Time frame: Blood samples were collected on Day 8, 9, 10, 31, 32, 33, 54, 55 and 56 of the study.

Secondary outcomes

  1. Occurrence of Adverse Events

    Clinical presentation characteristics, severity, onset time, duration of adverse events, management measures, outcomes, and the correlation with the investigational drug.

    Time frame: From enrollment to the end of the study on Day 59.

07

Study locations

1 site
  • Phase I Clinical Trial Research Center of Dongguan Kanghua Hospital
    Guangdong, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2022 to primary completion in Apr 2022, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2025
First posted
Jun 3, 2025
StartActual
Feb 21, 2022
Primary completionActual
Apr 25, 2022
CompletionActual
Mar 13, 2023
Last update
Jun 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07001501
Lead sponsor
Henan Genuine Biotech Co., Ltd.
Responsible party
Sponsor
First posted
Jun 3, 2025
Start date
Feb 21, 2022
Primary completion
Apr 25, 2022
Completion
Mar 13, 2023
Last update
Jun 3, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Azvudine · Itraconazole

Start the discussion